✦ LIBER ✦

305 RESULTS OF A MULTICENTRIC PHASE II RANDOMIZED TRIAL WITH DOCETAXEL (D) ± ESTRAMUSTINE (E) AS FIRST LINE CHEMOTHERAPY FOR PATIENTS (PTS) WITH HORMONE-REFRACTORY ADVANCED PROSTATE CANCER (HRPC)

✍ Scribed by O. Caffo; E. Comploj; T. Sava; G. Mansueto; F. Zustovich; R. Segati; C. Sacco; A. Perin; G. Pappagallo; F. Valduga; M. Frisinghelli; M. Centonze; E. Galligioni

Book ID: 119617637
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 316 KB
Volume: 6
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(07)60304-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel, with or without estramustine

Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial

✍ Orazio Caffo; Teodoro Sava; Evi Comploj; Annamaria Fariello; Fable Zustovich; Ro 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

IMPACT OF DOCETAXEL (D) – BASED CHEMOTHE

IMPACT OF DOCETAXEL (D) – BASED CHEMOTHERAPY ON QUALITY OF LIFE (QOL) OF PATIENTS (PTS) WITH HORMONE- REFRACTORY PROSTATE CANCER (HRPC): RESULTS FROM A RANDOMISED PHASE II TRIAL WITH D ± ESTRAMUSTINE (E)

✍ O. Caffo; T. Sava; E. Comploj; Z. Zustovich; R. Segati; A. Fariello; A. Perin; C 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 71 KB

Phase II randomised trial of docetaxel (

Phase II randomised trial of docetaxel (D), estramustine (E) and prednisone (P) — Two schedules — versus mitoxantrone (M) and prednisone in patients (PTS) with hormone refractory prostate cancer (HRPC)

✍ S. Qudard; E.B. Banu; E. Voog; H. Hardy-Bessard; C. Linassier; P. Beuzeuboe; A. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 187 KB

Early results of a multicenter phase 2 s

Early results of a multicenter phase 2 study: Weekly docetaxel and intermittent estramustin as combination chemotherapy in patients with hormone-refractory prostate cancer (HRPC)

✍ U. Steiner; K. Miller; S. Machtens; B. Backhaus; M. Siegsmund 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 226 KB

Phase II study of sequential chemotherap

Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer

✍ Galli, L; Fontana, A; Galli, C; Landi, L; Fontana, E; Antonuzzo, A; Andreuccetti 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 120 KB

299 POSTER Randomized phase II trial of

299 POSTER Randomized phase II trial of irofulven/prednisone, irofulven/capecitabine/prednisone, or mitoxantrone/prednisone in hormone refractory prostate cancer (HRPC) patients failing first-line docetaxel: preliminary results

✍ L. Hart; J. Hainsworth; T. Ciuleanu; S. Oudard; E. Berger; J. Alexandre; K. Chi; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB